Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma

Abstract Background Although perioperative treatment has been the standard of care for resectable gastric cancer in the West, postoperative adjuvant chemotherapy is still the standard in Japan. We conducted the first phase 2 trial to investigate the efficacy and safety of neoadjuvant docetaxel, oxal...

Full description

Bibliographic Details
Main Authors: Yukinori Kurokawa, Tomono Kawase, Atsushi Takeno, Haruna Furukawa, Ryo Yoshioka, Takuro Saito, Tsuyoshi Takahashi, Toshio Shimokawa, Hidetoshi Eguchi, Yuichiro Doki
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Annals of Gastroenterological Surgery
Subjects:
docetaxel, oxaliplatin, and S‐1
esophagogastric junction tumor
gastroesophageal junction cancer
neoadjuvant treatment
preoperative chemotherapy
Online Access:https://doi.org/10.1002/ags3.12632

Internet

https://doi.org/10.1002/ags3.12632

Similar Items